<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chan CK</submitter><funding>NIA NIH HHS</funding><pagination>1415-1426</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9969328</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>86(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Neuropsychiatric symptoms (NPS) among cognitively normal older adults are increasingly recognized as risk factors for cognitive decline and impairment. However, the underlying mechanisms remain unclear.&lt;h4>Objective&lt;/h4>To examine whether biomarkers of Alzheimer's disease (amyloid burden) and cerebrovascular disease (white matter hyperintensity (WMH) volume) modify the association between NPS and cognitive decline among cognitively unimpaired older adults.&lt;h4>Methods&lt;/h4>Analyses included 193 cognitively unimpaired participants (M age = 70 years) from the BIOCARD study, including 148 with PET amyloid and WMH biomarker data. NPS were measured with Neuropsychiatric Inventory and Geriatric Depression Scale scores. Linear mixed effects models were used to examine the associa</pubmed_abstract><journal>Journal of Alzheimer's disease : JAD</journal><pubmed_title>Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.</pubmed_title><pmcid>PMC9969328</pmcid><funding_grant_id>P30 AG066507</funding_grant_id><funding_grant_id>U19 AG033655</funding_grant_id><pubmed_authors>Albert M</pubmed_authors><pubmed_authors>Wang MC</pubmed_authors><pubmed_authors>Chan CK</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Pettigrew C</pubmed_authors><pubmed_authors>Rosenberg PB</pubmed_authors><pubmed_authors>Soldan A</pubmed_authors><pubmed_authors>BIOCARD Research Team</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.</name><description>&lt;h4>Background&lt;/h4>Neuropsychiatric symptoms (NPS) among cognitively normal older adults are increasingly recognized as risk factors for cognitive decline and impairment. However, the underlying mechanisms remain unclear.&lt;h4>Objective&lt;/h4>To examine whether biomarkers of Alzheimer's disease (amyloid burden) and cerebrovascular disease (white matter hyperintensity (WMH) volume) modify the association between NPS and cognitive decline among cognitively unimpaired older adults.&lt;h4>Methods&lt;/h4>Analyses included 193 cognitively unimpaired participants (M age = 70 years) from the BIOCARD study, including 148 with PET amyloid and WMH biomarker data. NPS were measured with Neuropsychiatric Inventory and Geriatric Depression Scale scores. Linear mixed effects models were used to examine the associa</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T00:36:16.244Z</modification><creation>2025-04-04T00:36:16.244Z</creation></dates><accession>S-EPMC9969328</accession><cross_references><pubmed>35213370</pubmed><doi>10.3233/JAD-215267</doi><doi>10.3233/jad-215267</doi></cross_references></HashMap>